Recent ASCIA website updates that are relevant to anaphylaxis and allergy include:

New ASCIA Management Summary for Young Adults with allergies to transition from paediatric to adult medical care - developed for health professionals to complete to support continuity of care.

ASCIA Anaphylaxis Checklist for Young Adults with allergies to transition from paediatric to adult care - updated to include a link to 250K for young adults and make it easier to read.

ASCIA Anaphylaxis Facts for Parents and Carers – updated to include current information and make it easier to read.

New peanut allergy treatment program for babies in Australia - ten paediatric hospitals across five states have introduced a global first nation-wide peanut oral immunotherapy (OIT) program.

ASCIA application for MBS item for supervised oral food challenges - ASCIA has lodged an application for an MBS item number to improve access to supervised oral food challenges.

ASCIA anaphylaxis e-training reports - for the first time since ASCIA anaphylaxis e-training was introduced in 2010, reports have been developed based on mandatory feedback surveys. 

ASCIA Guidelines - Adrenaline (Epinephrine) Injector Prescription and ASCIA Guidelines - Acute Management of Anaphylaxis - updated to include EpiPen® Jr, EpiPen® and Anapen® 500 devices.

Request for initial adrenaline injector to be provided on PBS Authority prescription by clinical immunology/allergy specialist - updated to make the form easier to find on the ASCIA website.

ASCIA Adverse Reactions to Complementary and Alternative Medicine FAQ - updated to include information about allergic reactions to Andrographis paniculata.

ASCIA Guide for Milk Substitutes in Cow’s Milk Allergy - updated due to Alfaré^® extensively hydrolysed formula being discontinued in Australia and removed from the PBS from 1 August 2024.

This news item was issued on 7 August by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.